{"id":5611,"date":"2024-06-13T16:25:02","date_gmt":"2024-06-13T16:25:02","guid":{"rendered":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/?p=5611"},"modified":"2024-06-14T14:15:51","modified_gmt":"2024-06-14T14:15:51","slug":"urnov","status":"publish","type":"post","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/urnov\/","title":{"rendered":"Fyodor Urnov, PhD"},"content":{"rendered":"

\"\"<\/p>\n

Fyodor Urnov is a Professor of Molecular Therapeutics at UC Berkeley and a Scientific Director at its Innovative Genomics Institute (IGI). He co-developed the toolbox of human genome and epigenome editing, co-named genome editing, and was on the team that advanced all of its first-in-human applications to the clinic. He also led the effort that identified the genome editing target for an approved medicine to treat sickle cell disease and beta-thalassemia. A major goal for the field of genome editing and a key focus of Fyodor’s work is expanding access to CRISPR therapies for genetic disease. As part of that effort Fyodor directs the Danaher-IGI Beacon for CRISPR Cures – a first-in-class academia-industry partnership developing and advancing to the clinic scalable CRISPR-based approaches to treat diseases of the immune system.<\/p>\n","protected":false},"excerpt":{"rendered":"

Fyodor Urnov is a Professor of Molecular Therapeutics at UC Berkeley and a Scientific Director at its Innovative Genomics Institute (IGI). He co-developed the toolbox of human genome and epigenome editing, co-named genome editing, and was on the team that advanced all of its first-in-human applications to the clinic. He also led the effort that […]<\/p>\n","protected":false},"author":6,"featured_media":5612,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-5611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-creative"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/comments?post=5611"}],"version-history":[{"count":2,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5611\/revisions"}],"predecessor-version":[{"id":5697,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5611\/revisions\/5697"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media\/5612"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media?parent=5611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/categories?post=5611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/tags?post=5611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}